It is widely known that the use of cannabis increases appetite, but how could it combat obesity? It seems that cannabis would have the opposite result for those wanting to lose weight and decrease their BMI. However, researchers are looking into the effects cannabis use has for treating cancer patients (wanting to increase their appetite), versus people who want to treat obesity issues. Similarly to the use of cannabis, eating can stimulate pleasure centers in our brain which is beneficial to those that have failed to increase their weight.
This paper will look at the endocannabinoids role in controlling appetite if they can be used to treat obesity.
Here is the full scientific article if you wish to download it.
Since the discovery of the endocannabinoid sysmtem in 1992 by the Hebrew University in Jerusalem the research into the endocannabinoid system and the human bodies endocannabinoids has only continued to expand and increase. We needed to understand what these things where and what they have been up to in our bodies for so long. The potential findings for the causes and solutions to many of our bodies ailments where endless.
26 years later the advances in this area have come along greatly but further research is needed to understand the exact reasons as to why certain endocannabinoids work in certain ways based on certain conditions and causes or due to the introduction of different external factors i.e. cannabis or opiate based medications. One thing we do know for a fact is that endocannabinoids play an important role in the endocannabinoid systems purpose of providing balance within our bodies.
This sysmtem and its different pathways and receptors influence our memory, sleep, appetite, energy & stress levels, reproduction, how our organs and immune systems work to name but a few.
The data reviewed here support an important role of endocannabinoids and CB1 cannabinoid receptors in the processes that normally regulate appetite and eating behaviour. The additional involvement of cannabinoid-sensitive mechanisms in the peripheral regulation of adiposity and energy balance indicates that endocannabinoid systems represent a potentially unique target for the treatment of disorders of appetite and body weight regulation.
The combined ability of rimonabant to alter fat metabolism and glucose utilisation, promote weight loss, and to suppress food intake suggests that CB1 receptor antagonists may be powerful tools in the treatment of obesity, metabolic syndrome, cardiovascular disease, type 2 diabetes and atherogenesis.